Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Odyssey Therapeutics announced positive clinical proof-of-concept results from a Phase 2a trial of OD-001, a novel oral RIPK2 scaffolding inhibitor for moderate to severe ulcerative colitis. They reported strong financials including $464 million in pro-forma cash after their recent IPO and private placement, providing runway into late 2028. The com…